Take­da to pull lung can­cer drug Exkiv­i­ty world­wide af­ter con­fir­ma­to­ry tri­al dis­ap­point­ment

Take­da is vol­un­tar­i­ly with­draw­ing its non-small cell lung can­cer drug Exkiv­i­ty from the glob­al mar­ket — start­ing with the US — months af­ter it was re­vealed the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.